Conjugated
Estrogens (Premarin)
Category:
Description:
Indications:
-
Menopausal
vasomotor symptoms (hot flashes, etc.)
-
Atrophic
vaginitis and kraurosis vulvae
-
Female
hypogonadism
-
Female
castration and primary ovarian failure
-
Breast
cancer (palliation only)
-
Prostatic
carcinoma
-
Osteoporosis
prophylaxis
-
Postpartum
breast engorgement
-
Abnormal
uterine bleeding due to hormonal imbalance
Contraindications:
-
Known
or suspected breast cancer (except those being treated for metastatic
disease)
-
Known
or suspected estrogen-dependent neoplasia
-
Known
or suspected pregnancy
-
Undiagnosed
abnormal genital bleeding
-
Current
or history of thrombophlebitis, thrombosis, thromboembolic disorders
(except when used in breast or prostatic cancer treatment).
Precautions:
-
Pregnancy
category X
-
Use
with caution in nursing mothers and patients with hypertension,
diabetes, asthma, epilepsy, migraine, cardiac or renal dysfunction,
history of depression, pre-existing uterine leiomyotoma, history of
jaundice during pregnancy, impaired liver function, metabolic bone
disorders and in young women (and men).
-
Take
with food to avoid GI side effects.
-
May
decrease glucose intolerance in diabetic patients.
-
Discontinue
therapy and contact health care provider if pregnancy is suspected.
Adverse
Reactions (Side Effects):
-
Rash,
acne, alopecia, hirsutism
-
Abnormal
menstrual bleeding, changes in cervical secretions
-
Edema,
weight change
-
Depression,
insomnia, somnolence
-
Nausea
|
Dosage:
-
Administered
orally, vaginally and IV injection
-
Menopausal
vasomotor symptoms: 1.25mg per day
-
Atrophic
vaginitis and kraurosis vulvae: 0.3-1.25mg orally, intravaginally and
topically per day depending on tissue response
-
Female
hypogonadism: 2.5-7.5mg per day in divided doses for 20 days, then
rest for ten days, then repeat schedule until bleeding occurs
-
Female
castration and primary ovarian failure: 1.25mg per day cyclically,
adjusted to lowest dose for individual
-
Breast
cancer (palliation only): 10mg tid for at least three months
-
Prostatic
carcinoma: 1.25-2.5mg tid
-
Osteoporosis
prophylaxis: 1.25mg per day, cyclically
-
Postpartum
breast engorgement: 3.75mg q4h for 5 doses or 1.25mg q4h for 5 days
-
Abnormal
uterine bleeding due to hormonal imbalance: 25mg IM or IV injection,
repeat in 6-12 hours if needed
For more information on the use of conjugated estrogens, read:
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|